Absci Shares Are Trading Higher After the Company Highlighted Progress and Updates Across Its Proprietary Pipeline and Leading AI Platform on 2024 R&D Day. Its Drug Candidate Was Selected for ABS-201, an Anti-PRLR Antibody in Development for...

Absci的股票在公司強調其專有管道和領先的人工智能平台在2024年研發日上的進展和更新後交易上漲。其藥物候選者被選爲ABS-201，一種正在開發的抗PRLR抗體用於...

Benzinga · 2024/12/12 21:38

Absci Shares Are Trading Higher After the Company Highlighted Progress and Updates Across Its Proprietary Pipeline and Leading AI Platform on 2024 R&D Day. Its Drug Candidate Was Selected for ABS-201, an Anti-PRLR Antibody in Development for Androgenic Alopecia.

Absci的股票在公司在2024年研發日上強調其專有管線和領先的人工智能平台的進展和更新後交易上漲。其藥物候選者被選中用於ABS-201，一種正在開發中的針對雄激素性脫髮的抗PRLR抗體。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。